Richard Todd Stravitz
Research Subjects
Richard Todd Stravitz has a total of 54 co-authors. Here are the top co-authors by number of shared publications:
Adrian H. Cotterell
Liver Transplant Program, Hume‐Lee Transplant Center, Virginia Commonwealth University Medical Center, Richmond, VA, USA
3 shared publicationsArun J. Sanyal
Liver Transplant Program, Hume‐Lee Transplant Center, Virginia Commonwealth University Medical Center, Richmond, VA, USA
3 shared publicationsDouglas M. Heuman
Liver Transplant Program, Hume‐Lee Transplant Center, Virginia Commonwealth University Medical Center, Richmond, VA, USA
3 shared publicationsMarc P. Posner
Liver Transplant Program, Hume‐Lee Transplant Center, Virginia Commonwealth University Medical Center, Richmond, VA, USA
3 shared publicationsMitchell L. Shiffman
Liver Transplant Program, Hume‐Lee Transplant Center, Virginia Commonwealth University Medical Center, Richmond, VA, USA
3 shared publicationsRichard K. Sterling
Liver Transplant Program, Hume‐Lee Transplant Center, Virginia Commonwealth University Medical Center, Richmond, VA, USA
3 shared publications
Latest Publications
- Open Access
- 11 October 2014
- Published by Wolters Kluwer Health in Liver Transplantation
- Vol. 21 (1) , 4-12
Therapeutic hypothermia in acute liver failure: A multicenter retrospective cohort analysis
The benefit of therapeutic hypothermia (TH) in acute liver failure (ALF) has not been previously demonstrated in a controlled fashion. This study sought to determine the impact of TH on 21‐day survival and complications in ALF patients at high risk for cerebral edema. This was a retrospective cohort study of ALF patients in the US Acute Liver Failure Study Group with grade III or IV hepatic encephalopathy. TH (32°C‐35°C) was used in 97 patients (8%); 1135 (92%) who were not cooled were controls. Intracranial pressure was monitored in 38 TH ALF patients (39.2% versus 22% of controls, P < 0.001). Rates of bleeding (12% for both) and bloodstream (17% versus 18%) and tracheal infections (21% versus 23%, P > 0.5 for all) were similar. Unadjusted 21‐day overall (62% versus 60%) and transplant‐free survival rates (45% versus 39%, P > 0.4 for both) were similar. Multivariate models were created for acetaminophen (APAP) patients (n = 582) and non‐APAP patients (n = 613). For APAP patients, the Model for End‐Stage Liver Disease [MELD; odds ratio (OR) = 0.91 per increment, 95% confidence interval (CI) = 0.89‐0.94, P < 0.001] and vasopressors (OR = 0.16, 95% CI = 0.11‐0.24, P < 0.001) were associated with decreased 21‐day spontaneous survival. Survival was improved with TH in APAP patients who were P < 0.001) and vasopressors (OR = 0.60, 95% CI = 0.40‐0.90, P = 0.01) were associated with worse outcomes, whereas TH had no impact (P = 0.93). In conclusion, TH in ALF was not associated with increased bleeding or infections. Although young APAP ALF patients may benefit, TH did not consistently affect 21‐day survival. A prospective trial is required to clarify the utility of TH in ALF patients. Liver Transpl 21:4‐12, 2015. © 2014 AASLD.
- 11 October 2014
- Published by Wolters Kluwer Health in Liver Transplantation
- Vol. 21 (1) , 4-12
Open AccessTherapeutic hypothermia in acute liver failure: A multicenter retrospective cohort analysis
The benefit of therapeutic hypothermia (TH) in acute liver failure (ALF) has not been previously demonstrated in a controlled fashion. This study sought to determine the impact of TH on 21‐day survival and complications in ALF patients at high risk for cerebral edema. This was a retrospective cohort study of ALF patients in the US Acute Liver Failure Study Group with grade III or IV hepatic encephalopathy. TH (32°C‐35°C) was used in 97 patients (8%); 1135 (92%) who were not cooled were controls. Intracranial pressure was monitored in 38 TH ALF patients (39.2% versus 22% of controls, P < 0.001). Rates of bleeding (12% for both) and bloodstream (17% versus 18%) and tracheal infections (21% versus 23%, P > 0.5 for all) were similar. Unadjusted 21‐day overall (62% versus 60%) and transplant‐free survival rates (45% versus 39%, P > 0.4 for both) were similar. Multivariate models were created for acetaminophen (APAP) patients (n = 582) and non‐APAP patients (n = 613). For APAP patients, the Model for End‐Stage Liver Disease [MELD; odds ratio (OR) = 0.91 per increment, 95% confidence interval (CI) = 0.89‐0.94, P < 0.001] and vasopressors (OR = 0.16, 95% CI = 0.11‐0.24, P < 0.001) were associated with decreased 21‐day spontaneous survival. Survival was improved with TH in APAP patients who were P < 0.001) and vasopressors (OR = 0.60, 95% CI = 0.40‐0.90, P = 0.01) were associated with worse outcomes, whereas TH had no impact (P = 0.93). In conclusion, TH in ALF was not associated with increased bleeding or infections. Although young APAP ALF patients may benefit, TH did not consistently affect 21‐day survival. A prospective trial is required to clarify the utility of TH in ALF patients. Liver Transpl 21:4‐12, 2015. © 2014 AASLD.
- 12 July 2014
- Published by Wiley in Liver International
- Vol. 35 (2) , 370-380
Two‐year outcomes in initial survivors with acute liver failure: results from a prospective, multicentre study
Background & Aims: The long‐term clinical outcomes in initial survivors with acute liver failure (ALF) are not well known. The aim of this study was to provide an overview of the 2‐year clinical outcomes among initial survivors and liver transplant (LT) recipients that were alive 3 weeks after enrolment in the Acute Liver Failure Study Group (ALFSG).Methods: Outcomes in adult ALFSG patients that were enrolled between 1998 and 2010 were reviewed.Results: Two‐year patient survival was significantly higher in the 262 LT recipients (92.4%) compared to the 306 acetaminophen (APAP) spontaneous survivors (SS) (89.5%) and 200 non‐APAP SS (75.5%) (P < 0.0001). The causes of death were similar in the three groups but the time to death was significantly longer in the LT recipients (P < 0.0001). Independent predictors of 2‐year mortality in the APAP group were a high serum phosphate level and patient age (c‐statistic = 0.65 (0.54, 0.76)), patient age and days from jaundice to ALF onset in the non‐APAP group (c‐statistic = 0.69 (0.60, 0.78)), and patient age, days from jaundice, and higher coma grade in the LT recipients (c‐statistic = 0.74 (0.61, 0.87)). The LT recipients were significantly more likely to be employed and have a higher educational level (P < 0.05).Conclusions: Two‐year outcomes in initial survivors of ALF are generally good but non‐APAP patients have a significantly lower survival which may relate to pre‐existing medical comorbidities. Spontaneous survivors with APAP overdose experience substantial morbidity during follow‐up from ongoing psychiatric and substance abuse issues.
- 12 July 2014
- Published by Wiley in Liver International
- Vol. 35 (2) , 370-380
Two‐year outcomes in initial survivors with acute liver failure: results from a prospective, multicentre study
Background & Aims: The long‐term clinical outcomes in initial survivors with acute liver failure (ALF) are not well known. The aim of this study was to provide an overview of the 2‐year clinical outcomes among initial survivors and liver transplant (LT) recipients that were alive 3 weeks after enrolment in the Acute Liver Failure Study Group (ALFSG).Methods: Outcomes in adult ALFSG patients that were enrolled between 1998 and 2010 were reviewed.Results: Two‐year patient survival was significantly higher in the 262 LT recipients (92.4%) compared to the 306 acetaminophen (APAP) spontaneous survivors (SS) (89.5%) and 200 non‐APAP SS (75.5%) (P < 0.0001). The causes of death were similar in the three groups but the time to death was significantly longer in the LT recipients (P < 0.0001). Independent predictors of 2‐year mortality in the APAP group were a high serum phosphate level and patient age (c‐statistic = 0.65 (0.54, 0.76)), patient age and days from jaundice to ALF onset in the non‐APAP group (c‐statistic = 0.69 (0.60, 0.78)), and patient age, days from jaundice, and higher coma grade in the LT recipients (c‐statistic = 0.74 (0.61, 0.87)). The LT recipients were significantly more likely to be employed and have a higher educational level (P < 0.05).Conclusions: Two‐year outcomes in initial survivors of ALF are generally good but non‐APAP patients have a significantly lower survival which may relate to pre‐existing medical comorbidities. Spontaneous survivors with APAP overdose experience substantial morbidity during follow‐up from ongoing psychiatric and substance abuse issues.
- 2 July 2009
- Published by Wiley in Liver International
- Vol. 29 (7) , 1071-1077
Effect of hyponatraemia on outcomes following orthotopic liver transplantation
Background: Hyponatraemia increases risk of adverse outcomes following orthotopic liver transplantation (OLT), but it is unclear whether improvement of pretransplant hyponatraemia ameliorates post‐transplant complications.Aims: To assess impact of pretransplant hyponatraemia on post‐transplant outcomes.Methods: We performed a retrospective analysis of 213 patients with cirrhosis who underwent liver transplantation. Patients with serum sodium ≤130 mEq/L immediately before transplantation (‘hyponatraemia at OLT’; n=34) were compared with those who had experienced hyponatraemia but subsequently improved to a serum sodium >130 mEq/L at transplantation (‘resolved hyponatraemia’; n=56) and to those without history of hyponatraemia before transplantation (‘never hyponatraemic’; n=123). Primary endpoint was survival at 180 days post‐OLT. Secondary outcomes included time until discharge alive, complications during hospitalization, length of time ventilated and length of post‐transplant intensive care unit stay.Results: There was no survival difference at 180 days post‐OLT between groups. After transplantation, patients with either hyponatraemia at OLT or resolved hyponatraemia had longer time until discharge alive and had higher rates of delirium, acute renal failure, acute cellular rejection and infection than those who were never hyponatraemic. As compared with patients with hyponatraemia at OLT, those with resolved hyponatraemia were more likely to be discharged alive within 3 weeks, but other outcomes, including survival, did not differ significantly.Conclusions: We conclude that hyponatraemia at any time before liver transplantation is associated with adverse post‐transplant outcome, even when hyponatraemia has resolved.
- 2 July 2009
- Published by Wiley in Liver International
- Vol. 29 (7) , 1071-1077
Effect of hyponatraemia on outcomes following orthotopic liver transplantation
Background: Hyponatraemia increases risk of adverse outcomes following orthotopic liver transplantation (OLT), but it is unclear whether improvement of pretransplant hyponatraemia ameliorates post‐transplant complications.Aims: To assess impact of pretransplant hyponatraemia on post‐transplant outcomes.Methods: We performed a retrospective analysis of 213 patients with cirrhosis who underwent liver transplantation. Patients with serum sodium ≤130 mEq/L immediately before transplantation (‘hyponatraemia at OLT’; n=34) were compared with those who had experienced hyponatraemia but subsequently improved to a serum sodium >130 mEq/L at transplantation (‘resolved hyponatraemia’; n=56) and to those without history of hyponatraemia before transplantation (‘never hyponatraemic’; n=123). Primary endpoint was survival at 180 days post‐OLT. Secondary outcomes included time until discharge alive, complications during hospitalization, length of time ventilated and length of post‐transplant intensive care unit stay.Results: There was no survival difference at 180 days post‐OLT between groups. After transplantation, patients with either hyponatraemia at OLT or resolved hyponatraemia had longer time until discharge alive and had higher rates of delirium, acute renal failure, acute cellular rejection and infection than those who were never hyponatraemic. As compared with patients with hyponatraemia at OLT, those with resolved hyponatraemia were more likely to be discharged alive within 3 weeks, but other outcomes, including survival, did not differ significantly.Conclusions: We conclude that hyponatraemia at any time before liver transplantation is associated with adverse post‐transplant outcome, even when hyponatraemia has resolved.
- 4 April 2008
- Published by Springer Nature in Neurocritical Care
- Vol. 9 (1) , 90-96
Therapeutic Hypothermia for Acute Liver Failure: Toward a Randomized, Controlled Trial in Patients with Advanced Hepatic Encephalopathy
Acute liver failure (ALF), the abrupt loss of liver function in a patient without previous liver disease, remains a highly mortal condition. Patients with ALF often succumb to their liver injury after the development of cerebral edema, resulting in intracranial hypertension and brain herniation. While the management of cerebral edema in ALF always includes the administration of osmotically active agents, osmotherapy often reduces intracranial pressure (ICP) insufficiently, such that herniation may be delayed but not prevented. Therapeutic hypothermia, the intentional reduction of body core temperature, has been increasingly used to treat cerebral edema in patients with traumatic and hypoxic brain injury. Data in animal models of ALF also suggest that hypothermia is effective in the prevention and treatment of cerebral edema, and case reports in humans have suggested that hypothermia is an effective bridge to orthotopic liver transplantation. A randomized, controlled trial comparing the management of ALF patients under normothermic and hypothermic conditions is a logical extension of these preliminary observations. Herein, we consider the many difficulties which will be encountered in the design of such a trial in patients with ALF at high risk of developing cerebral edema.
- 4 April 2008
- Published by Springer Nature in Neurocritical Care
- Vol. 9 (1) , 90-96
Therapeutic Hypothermia for Acute Liver Failure: Toward a Randomized, Controlled Trial in Patients with Advanced Hepatic Encephalopathy
Acute liver failure (ALF), the abrupt loss of liver function in a patient without previous liver disease, remains a highly mortal condition. Patients with ALF often succumb to their liver injury after the development of cerebral edema, resulting in intracranial hypertension and brain herniation. While the management of cerebral edema in ALF always includes the administration of osmotically active agents, osmotherapy often reduces intracranial pressure (ICP) insufficiently, such that herniation may be delayed but not prevented. Therapeutic hypothermia, the intentional reduction of body core temperature, has been increasingly used to treat cerebral edema in patients with traumatic and hypoxic brain injury. Data in animal models of ALF also suggest that hypothermia is effective in the prevention and treatment of cerebral edema, and case reports in humans have suggested that hypothermia is an effective bridge to orthotopic liver transplantation. A randomized, controlled trial comparing the management of ALF patients under normothermic and hypothermic conditions is a logical extension of these preliminary observations. Herein, we consider the many difficulties which will be encountered in the design of such a trial in patients with ALF at high risk of developing cerebral edema.
- 1 February 2008
- Published by Elsevier in The American Journal of Medicine
- Vol. 121 (2) , 119-126
Surveillance for Hepatocellular Carcinoma in Patients with Cirrhosis Improves Outcome
- 1 February 2008
- Published by Elsevier in The American Journal of Medicine
- Vol. 121 (2) , 119-126
Surveillance for Hepatocellular Carcinoma in Patients with Cirrhosis Improves Outcome
- 1 November 2007
- Published by Wolters Kluwer Health in Critical Care Medicine
- Vol. 35 (11) , 2498-2508
Intensive care of patients with acute liver failure: Recommendations of the U.S. Acute Liver Failure Study Group
To provide a uniform platform from which to study acute liver failure, the U.S. Acute Liver Failure Study Group has sought to standardize the management of patients with acute liver failure within participating centers. In areas where consensus could not be reached because of divergent practices and a paucity of studies in acute liver failure patients, additional information was gleaned from the intensive care literature and literature on the management of intracranial hypertension in non-acute liver failure patients. Experts in diverse fields were included in the development of a standard study-wide management protocol. Intracranial pressure monitoring is recommended in patients with advanced hepatic encephalopathy who are awaiting orthotopic liver transplantation. At an intracranial pressure of > or =25 mm Hg, osmotic therapy should be instituted with intravenous mannitol boluses. Patients with acute liver failure should be maintained in a mildly hyperosmotic state to minimize cerebral edema. Accordingly, serum sodium should be maintained at least within high normal limits, but hypertonic saline administered to 145-155 mmol/L may be considered in patients with intracranial hypertension refractory to mannitol. Data are insufficient to recommend further therapy in patients who fail osmotherapy, although the induction of moderate hypothermia appears to be promising as a bridge to orthotopic liver transplantation. Empirical broad-spectrum antibiotics should be administered to any patient with acute liver failure who develops signs of the systemic inflammatory response syndrome, or unexplained progression to higher grades of encephalopathy. Other recommendations encompassing specific hematologic, renal, pulmonary, and endocrine complications of acute liver failure patients are provided, including their management during and after orthotopic liver transplantation. The present consensus details the intensive care management of patients with acute liver failure. Such guidelines may be useful not only for the management of individual patients with acute liver failure, but also to improve the uniformity of practices across academic centers for the purpose of collaborative studies.
- 1 November 2007
- Published by Wolters Kluwer Health in Critical Care Medicine
- Vol. 35 (11) , 2498-2508
Intensive care of patients with acute liver failure: Recommendations of the U.S. Acute Liver Failure Study Group
To provide a uniform platform from which to study acute liver failure, the U.S. Acute Liver Failure Study Group has sought to standardize the management of patients with acute liver failure within participating centers. In areas where consensus could not be reached because of divergent practices and a paucity of studies in acute liver failure patients, additional information was gleaned from the intensive care literature and literature on the management of intracranial hypertension in non-acute liver failure patients. Experts in diverse fields were included in the development of a standard study-wide management protocol. Intracranial pressure monitoring is recommended in patients with advanced hepatic encephalopathy who are awaiting orthotopic liver transplantation. At an intracranial pressure of > or =25 mm Hg, osmotic therapy should be instituted with intravenous mannitol boluses. Patients with acute liver failure should be maintained in a mildly hyperosmotic state to minimize cerebral edema. Accordingly, serum sodium should be maintained at least within high normal limits, but hypertonic saline administered to 145-155 mmol/L may be considered in patients with intracranial hypertension refractory to mannitol. Data are insufficient to recommend further therapy in patients who fail osmotherapy, although the induction of moderate hypothermia appears to be promising as a bridge to orthotopic liver transplantation. Empirical broad-spectrum antibiotics should be administered to any patient with acute liver failure who develops signs of the systemic inflammatory response syndrome, or unexplained progression to higher grades of encephalopathy. Other recommendations encompassing specific hematologic, renal, pulmonary, and endocrine complications of acute liver failure patients are provided, including their management during and after orthotopic liver transplantation. The present consensus details the intensive care management of patients with acute liver failure. Such guidelines may be useful not only for the management of individual patients with acute liver failure, but also to improve the uniformity of practices across academic centers for the purpose of collaborative studies.
- Open Access
- 8 January 2007
- Published by Wiley in Alimentary Pharmacology & Therapeutics
- Vol. 25 (3) , 229-245
Review article: medical management of the liver transplant recipient – a primer for non‐transplant doctors
Summary: Background: Survival 10 years after orthotopic liver transplantation now approaches 65%. Consequently, community doctors must manage the metabolic and neoplastic complications of orthotopic liver transplantation in an ageing population.Aims: To review common sources of morbidity and mortality in long‐term orthotopic liver transplantation recipients, and to make evidence‐based recommendations regarding their management.Methods: Pertinent studies and reviews were identified by literature search through PubMed. Where evidence‐based recommendations could not be gleaned from the literature, expert opinion was obtained from syllabi of national meetings.Results: The two most common causes of morbidity and mortality in orthotopic liver transplantation recipients are atherosclerotic vascular disease andde novomalignancy. The pathogenesis of many complications begins before orthotopic liver transplantation, and many are potentially modifiable. Most complications, however, can be directly ascribed to immunosuppressive agents. Despite improvements in our understanding of the pathogenesis and epidemiology of the metabolic and neoplastic complications of orthotopic liver transplantation, remarkably few randomized‐controlled studies exist to define their optimal management.Conclusions: Orthotopic liver transplantation recipients experience and succumb to the same afflictions of old age as non‐transplant patients, but with greater frequency and at an earlier age. Most recommendations regarding surveillance for, and treatment of, medical complications of orthotopic liver transplantation remain based upon expert opinion rather than evidence‐based medicine.
- 8 January 2007
- Published by Wiley in Alimentary Pharmacology & Therapeutics
- Vol. 25 (3) , 229-245
Open AccessReview article: medical management of the liver transplant recipient – a primer for non‐transplant doctors
Summary: Background: Survival 10 years after orthotopic liver transplantation now approaches 65%. Consequently, community doctors must manage the metabolic and neoplastic complications of orthotopic liver transplantation in an ageing population.Aims: To review common sources of morbidity and mortality in long‐term orthotopic liver transplantation recipients, and to make evidence‐based recommendations regarding their management.Methods: Pertinent studies and reviews were identified by literature search through PubMed. Where evidence‐based recommendations could not be gleaned from the literature, expert opinion was obtained from syllabi of national meetings.Results: The two most common causes of morbidity and mortality in orthotopic liver transplantation recipients are atherosclerotic vascular disease andde novomalignancy. The pathogenesis of many complications begins before orthotopic liver transplantation, and many are potentially modifiable. Most complications, however, can be directly ascribed to immunosuppressive agents. Despite improvements in our understanding of the pathogenesis and epidemiology of the metabolic and neoplastic complications of orthotopic liver transplantation, remarkably few randomized‐controlled studies exist to define their optimal management.Conclusions: Orthotopic liver transplantation recipients experience and succumb to the same afflictions of old age as non‐transplant patients, but with greater frequency and at an earlier age. Most recommendations regarding surveillance for, and treatment of, medical complications of orthotopic liver transplantation remain based upon expert opinion rather than evidence‐based medicine.
- Open Access
- 29 June 2004
- Published by Wolters Kluwer Health in Liver Transplantation
- Vol. 10 (7) , 850-858
Effects of interferon treatment on liver histology and allograft rejection in patients with recurrent hepatitis C following liver transplantation
Recurrent hepatitis C after liver transplantation remains a significant cause of graft loss and retransplantation. Although treatment of recurrent hepatitis C with interferon-based regimens has become widely accepted as safe and can lead to sustained virologic clearance of hepatitis C virus (HCV) RNA, long-term histologic improvement and the risk of precipitating graft rejection remain controversial. The present study is a retrospective evaluation of the clinical and histological consequences of treating recurrent hepatitis C with interferon-based therapy in a selected group of liver transplant recipients. Twenty-three liver transplant recipients with recurrent hepatitis C and histologic evidence of progressive fibrosis completed at least 6 months of interferon, 83% of whom received pegylated-interferon α-2b; only 4 tolerated ribavirin. Overall, 11 patients (48%) had undetectable HCV RNA at the end of 6 months of treatment. Of these patients, 3 remained HCV RNA-negative on maintenance interferon monotherapy for 33 months, and the other 8 (35%) completed treatment and remained HCV RNA-undetectable 24 weeks after discontinuation of interferon. Overall necroinflammatory activity in liver biopsies obtained 2 years after HCV RNA became undetectable decreased significantly (7.73 ± 2.37 vs. 5.64 ± 2.94 units before and after treatment, respectively; P = .016). However, 5 of these 11 patients had no histologic improvement in follow-up liver histology. Liver biopsies in the 12 nonresponders demonstrated disease progression. Of the 23 patients treated with interferon, 8 (35%) had evidence of acute or chronic rejection on posttreatment liver biopsy, most of whom had no previous history of rejection (P < .01 for comparison of pretreatment and posttreatment prevalence of histologic rejection), and 2 experienced graft loss from chronic rejection, requiring retransplantation. In conclusion, interferon treatment of recurrent hepatitis C does not consistently improve histologic disease after virologic response, and it may increase the risk of allograft rejection. (Liver Transpl 2004;10:850-858.)
- 29 June 2004
- Published by Wolters Kluwer Health in Liver Transplantation
- Vol. 10 (7) , 850-858
Open AccessEffects of interferon treatment on liver histology and allograft rejection in patients with recurrent hepatitis C following liver transplantation
Recurrent hepatitis C after liver transplantation remains a significant cause of graft loss and retransplantation. Although treatment of recurrent hepatitis C with interferon-based regimens has become widely accepted as safe and can lead to sustained virologic clearance of hepatitis C virus (HCV) RNA, long-term histologic improvement and the risk of precipitating graft rejection remain controversial. The present study is a retrospective evaluation of the clinical and histological consequences of treating recurrent hepatitis C with interferon-based therapy in a selected group of liver transplant recipients. Twenty-three liver transplant recipients with recurrent hepatitis C and histologic evidence of progressive fibrosis completed at least 6 months of interferon, 83% of whom received pegylated-interferon α-2b; only 4 tolerated ribavirin. Overall, 11 patients (48%) had undetectable HCV RNA at the end of 6 months of treatment. Of these patients, 3 remained HCV RNA-negative on maintenance interferon monotherapy for 33 months, and the other 8 (35%) completed treatment and remained HCV RNA-undetectable 24 weeks after discontinuation of interferon. Overall necroinflammatory activity in liver biopsies obtained 2 years after HCV RNA became undetectable decreased significantly (7.73 ± 2.37 vs. 5.64 ± 2.94 units before and after treatment, respectively; P = .016). However, 5 of these 11 patients had no histologic improvement in follow-up liver histology. Liver biopsies in the 12 nonresponders demonstrated disease progression. Of the 23 patients treated with interferon, 8 (35%) had evidence of acute or chronic rejection on posttreatment liver biopsy, most of whom had no previous history of rejection (P < .01 for comparison of pretreatment and posttreatment prevalence of histologic rejection), and 2 experienced graft loss from chronic rejection, requiring retransplantation. In conclusion, interferon treatment of recurrent hepatitis C does not consistently improve histologic disease after virologic response, and it may increase the risk of allograft rejection. (Liver Transpl 2004;10:850-858.)
- 1 May 2003
- Published by Elsevier in Clinics in Liver Disease
- Vol. 7 (2) , 435-451
Drug-induced steatohepatitis
- 1 May 2003
- Published by Elsevier in Clinics in Liver Disease
- Vol. 7 (2) , 435-451
Drug-induced steatohepatitis